Targeting VEGFR2, Miyazawa et al. (67) have vaccinated pancreatic cancer patients with a VEGFR2-derived peptide (VEGF-169, HLA-A2402 restricted) and vaccinated in combination with gemcitabine treatment, the standard care for pancreatic cancer patients with metastatic or recurrent disease. Here, KDR is linked to pancreatic neoplasm.